Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety Study of MYL-1401H vs Neulasta in Breast Cancer Patients
NCT02467868Phase 3Completed
- Sponsor
- Mylan
- Start
- Mar 2015
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim in febrile neutropenia (FN) and neutropenia (2 arms), sponsored by Mylan. Primary endpoint: Duration of Severe Neutropenia. Started Mar 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
febrile neutropenia (FN)neutropenia
Beyond the preview
Go deeper on NCT02467868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467868.